Zika virus (ZIKV) specific neutralizing antibodies hold a great promise for 25 antibody-based interventions and vaccine design against ZIKV infection. 26 However, their development in infected patients remain unknown. Here, we 27 report on the dynamic development of a potent and protective ZIKV-specific 28 human antibody ZK2B10 initially isolated from a ZIKV convalescent individual 29 using next-generation sequencing (NGS). The unbiased repertoire analysis 30 showed dramatic changes in many families of heavy and light chain variable 31 regions. However, lineage tracing of ZK2B10 revealed limited somatic 32 hypermutation throughout the 12 months since the onset of symptom. In 33 particular, NGS-derived germline-like somatic variants neutralized and 34 protected mice from lethal challenge of ZIKV without detectable cross-reactivity 35 with Dengue virus (DENV). Site-directed mutagenesis identified two residues 36 within  chain, N31 and S91 that are essential to the functional maturation. The 37 dynamic features unveiled here will assist us to better understand the 38 pathogenesis of ZIKV infection and inform rational design of vaccines.
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However, the low frequency of 155 suggesting that ZK2B10 did not represent a major B cell lineage in the 156 repertoire spanning the acute and convalescent phases of ZIKV infection. In 157 addition, there appeared to be no correlation between the potency of a ZIKV 158 E-targeting mAb and its lineage expansion or prevalence, as indicated by the 159 low frequency of the ZK2B10 germline gene family. 160 We then determined the degree of somatic hypermutation (SHM) or 161 germline divergence of each time point from early acute phase to late 162 convalescent phase. As shown in Fig 1C, there is a significant increase in the 163 population of germline-like sequences at Day 15 for both heavy and light chains. 164 As a consequence, the average SHM of heavy,  chain and  chain repertoire 165 dropped to 6.25%, 5.92% and 5.91% on Day 15, respectively. Of note, the SHM 166 decreased in most V gene families on Day 15 without preference (S2 Fig.) . As 167 for the V H germline gene of ZK2B10, IGHV1-8, accounted for only 6.45% SHM 168 on Day 15 and for 7.23% to 13.60% in other time points (S2 Fig., left) . The V L 169 germline gene of ZK2B10, corresponding to presented 5.72% SHM 170 at Day 15, while 6.70% to 9.04% at other time points studied (S2 Fig., right) . 171 These results suggest a drastic shift in repertoire composition likely caused by clonal expansion than those from ZIKV-infected, DENV-immune individuals, 177 which with many derived from common memory B cell clones [19, 47] . 178 Interestingly, the similar pattern has also been reported for an HIV-1 patient 179 undergoing chronic infection in response to a rapidly mutating envelope spike 180 [44] . 181 We next determined changes in the CDR3 loop length. Due to the diversity 182 of the D gene, a rather dispersed distribution in HCDR3 loop length was 183 observed as compared to a steady, canonical CDR3 loop length distribution 184 obtained for  and  chains ( Fig 1D) . The HCDR3 loops were mainly distributed 185 at the range of 9-aa to 15-aa ( Fig 1D, left) . As for the light chain, 9-aa KCDR3 186 loops accounted for 79.3% to 88.2% of the  chain repertoire, while 9-aa to 11-187 aa LCDR3 loops accounted for 81.3% to 94.9% of the  chain repertoire ( Fig 2B) . Of note, due to the lack of a D gene, light chains do not possess 209 unambiguous sequence signatures for CDR3-based lineage tracing.
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Nonetheless, our data suggests that ZK2B10 lineage antibodies were induced 211 rapidly and transiently at the end of acute phase during ZIKV infection.
212
Interestingly, the majority of ZK2B10 somatic variants showed a germline 213 divergence of less than 5.0% in both heavy and  chain repertoires (Fig 2A, 214 low panel and Fig 2B) .
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To further study the maturation pathway of ZK2B10, we selected heavy chain somatic variants, 11 (2H-1, -2, -3, -4, -5, -6, -9, -10, -14, -15, and 240 -16) could be expressed when paired with WT ZK2B10  chain ( Fig 4A) . We 241 next measured their binding ability to E glycoprotein and E DIII of ZIKV by 12 242 ELISA. Among the 11 mAbs, 8 (2H-1, -4, -5, -6, -9, -10, -15, and -16) 243 demonstrated strong binding affinities for E and E DIII at the similar level to 244 ZK2B10, with the half-maximal effective concentrations (EC 50 ) ranging from 3.4 245 to 11.2 ng/ml, while the remaining 3 mAbs (2H-2, -3, and -14) showed weak 246 affinities ( Fig 4A) . These mAbs were then subjected to a plaque reduction 247 neutralization test against two ZIKV strains, GZ01 (Asian) and MR766 (African), 248 and DENV 2 ( Fig 4A) . Consistent with their binding abilities, the 8 strong 249 binders (2H-1, -4, -5, -6, -9, -10, -15, and -16) neutralized GZ01 and MR766 250 potently ( Fig 4A) . The half-maximal inhibitory concentrations (IC 50 ) range from 251 14.1 to 82.4 ng/ml, which are comparable to WT ZK2B10 and other potent E-252 targeting mAbs isolated from ZIKV-infected, DENV-naïve human subjects (Fig   253   4A ) [18, 20, 21, 24, 26] . Not surprisingly, 2H-2 failed to show detectable 254 potency (IC 50 >500 ng/ml to both GZ01 and MR766), 2H-3 showed only modest 255 neutralizing activity (IC 50 = 289.4 ng/ml to GZ01 and 334.1 ng/ml to MR766), 256 and 2H-14 failed to demonstrate high potency against ZIKV as well (IC 50 = 489.1 257 ng/ml to GZ01 and IC 50 >500 ng/ml to MR766) ( Fig 4A) . All these mAbs showed 258 no cross-neutralizing activities with DENV 2 ( Fig 4A) . Strikingly, with 100% 259 identity to IGHV1-8, 2H-1 showed high affinity for full-length E and E DIII of 260 ZIKV with EC 50 values of 5.3 ng/ml and 3.4 ng/ml, respectively ( Fig 4A) .
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Meanwhile, 2H-1 potently neutralized GZ01 and MR766, with IC 50 values of 262 14.1 ng/ml and 19.4 ng/ml, respectively ( Fig 4A) . Notably, 1006 out of 1715 263 (58.7%) ZK2B10-like heavy chains from Day 15 were identical to 2H-1, 13 264 confirming that this germline-like mAb lineage emerged at the peak of 265 plasmablast response. According to the alignment compared to IGHV1-8 266 germline sequence, the functional loss of 2H-2, -3 and -14 could be explained 267 potentially by the mutation of D39 located toward the end of HCDR1 ( Fig 3A) .
268
As for 11 synthesized ZK2B10-like  chains, 7 (2L-1, -2, -3, -6, -8, -9, and -11) 269 were expressible when paired with WT ZK2B10 heavy chain. Surprisingly, 5 270 (2L-1, -3, -8, -9, and -11) of these 7  variants failed to bind ZIKV E or E DIII 271 combined with undetectable neutralizing activities against ZIKV ( Fig 4B) .
272
Among them, the sequence of 2L-1 is 100% identical to IGLV1-47 and 273 represents a large portion of the Day 15  chain population (147 out of 495, 274 29.7%) ( Fig 4B) . The reconstituted mAbs containing 2L-2 and 2L-6 275 demonstrated rather weak binding and neutralizing activities compared to WT 276 ZK2B10 ( Fig 4B) . Together with the sequence alignments, these patterns 277 presume to that S31N on LCDR1 and in A91S on LCDR3 could be critical for 278 the maturation of ZK2B10  chain ( Fig 3B) .
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To summarize, the results from functional characterizations of ZK2B10 Protective potential of ZK2B10 somatic variants in a mouse model 288 Previously, we have demonstrated ZK2B10 can protect mouse from lethal ZIKV 289 infection and microcephaly [24, 30] . Such animal study will not only confirm the 290 accuracy of our repertoire analyses but also provide clues as to the functional 291 diversity of the ZK2B10 lineage in vivo. To this end, we tested the in vivo 292 protection against ZIKV lethal infection of representative ZK2B10 somatic 293 variants in AG6 mice (C57BL/6 mice deficient in IFNα, -β, and -γ receptors) 294 following protocol highlighted in Fig 4C [ 24, 30, 48, 49] . Briefly, we 295 administrated 300μg of each ZK2B10-like mAb, ZK2B10 as positive control, or 296 MERS-4 as negative control to groups of four AG6 mice, from 4 to 6 weeks in 297 age, via the intraperitoneal (i.p.) route ( Fig 4C) [50]. On the following day, the 298 animals were challenged with 10 4 plaque-forming units (PFUs) of ZIKV Asian 299 strain GZ01 via the intraperitoneal (i.p.) route ( Fig 4C) . Animals were monitored 300 for the survival rate up to 14 days after ZIKV challenge, and for viral RNA level 301 in blood on 5 and 12 days after ZIKV challenge ( Fig 4C) . As expected, in vivo 302 protection of mAbs was correlated with their in vitro neutralization, as 303 previously reported [30] . For example, the heavy chain variants with potent 304 neutralizing activities in vitro (2H-1, -4, -6, -9, -10, -15 and -16) provided 305 complete protection with a survival rate of 100% up to 14 days after ZIKV 306 challenge ( Fig 4D) . The RNA load in these groups was suppressed in blood 307 with distinguishable level from the MERS-4 group (Fig 4F) . Exceptionally, 2H-15 308 2, -3 and -14 failed to offer any protection with a median survival time of 7.25 309 to 8 days after ZIKV challenge ( Fig 4D) . The viral RNA levels measured in mice 310 treated by them were 3.72 to 4.45 log 10 greater on average than the ZK2B10 311 group on day 5 after ZIKV challenge, respectively ( Fig 4F) . In contrast, all of Critical residues for ZK2B10 functional maturation 319 To the further investigation of the maturation pathway of the ZK2B10 lineage, 320 we performed reverse mutagenesis and structural analysis to identify 'hotspot' 321 residues. Before that, we aligned the amino acid sequences of representative 322 ZK2B10 heavy and  chain variants with their putative germline genes, IGHV1-323 8 and IGLV1-47, respectively (Fig 3) . For heavy chain, 2H-2, 2H-3, and 2H-14 324 lose their potency to ZIKV both in vitro and in vivo. These 3 heavy chains 325 possess a single substitution mutation at the D39 with respect to their germline 326 gene ( Fig 3A) . To test that, we conducted reverse mutagenesis on 2H-2 (A39D), activities, approaching the level of WT ZK2B10. Due to the use of a different 331 V H germline gene, IGHV1-69, the 2H-2 (A39D) mutant was ineffective ( Fig 5A) . 332 This result suggested that the ZK2B10 lineage has a restricted V H gene usage 333 to achieve high affinity and potency against ZIKV. Based on the crystal 334 structure of ZK2B10 in complex with ZIKV E DIII, 4 residues within HCDR3 loop 335 (Y111, Y114, Y116 and Y118) were directly involved in the contact interface 336 [31]. Although D39 is on HCDR1 loop, it forms hydrogen bonds with Y115 and 337 Y117 on the opposite side of the HCDR3 loop, thus stabilizing the HCDR3 338 conformation ( Fig 5C) . These results provide further evidence that the ZK2B10 339 lineage was indeed generated during the naïve B cell response to acute ZIKV 340 infection, with critical residues encoded by the germline gene. For  chain 341 variants, two critical mutations were identified that potentially contribute to the 342 maturation of ZK2B10 lineage ( Fig 3B) . One such mutation, located on the 343 LCDR1 loop, is N31, which is shared by the weak-functional variants 2L-2 and 344 2L-6, as well as WT ZK2B10  chain ( Fig 3B) . The other is at position 91 on 345 LCDR3 loop, which is S91 in WT ZK2B10  chain but predominantly A91 in all 346 these weak-or non-functional  chain variants ( Fig 3B) . Thus, N31N and S91 347 could be the critical mutations for ZK2B10  chain maturation. We first 348 examined the effect of these two mutations individually by performing site-349 directed mutagenesis on 2L-1, which is 100% identical to germline gene 350 IGLV1-47. Neither S31N nor A91S could effectively render the germline 351 antibody functional ( Fig 5B) . We then introduced a double mutation 17 352 (S31N+A91S) into 2L-1, which, as expected, bound to ZIKV E and E DIII with 353 high affinity and potently neutralized ZIKV at the same level of WT ZK2B10 (Fig   354   5B ). As shown by the crystal structure, 5 residues within ZK2B10  chain (N31, 355 N32, Y33, R51, D94 and L96) directly involved in the in the contact interface 356 [31]. For the two identified critical residues, N31 directly interacts with T309 on 357 ZIKV E DIII, while S91 forms a hydrogen bond with N32, which interacts with 358 T335 on ZIKV E DIII ( Fig 5D) . In brief, our combined analyses of NGS data, 359 antibody functions, and complex structure confirm that residues N31 and S91 Two unique aspects of our study are worth highlighting here. One is based 375 on the effective germline-coded antibody response represented by ZK2B10 376 lineage. We report here that there was a significant increase in germline-like 
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The other unique aspect of our study was the assist in the rational design 405 of a safe and effective vaccine. As we previously reported that ZK2B10, as well 406 as other E DIII-specific mAbs, are ZIKV-specific, potent neutralizing and 407 protective in mice from a lethal ZIKV challenge [18, 23, 24, 30] . The identified 408 epitope reveal that ZK2B10 bind to residues within the lateral ridge of DIII and 409 blocks infection at a post-attachment step as other E DIII-specific potent 410 neutralizing mAbs [31, 47] . Beyond that, DIII-specific antibodies give essential 411 contribution to controlling ZIKV as they correlated positively with high 412 neutralization titers and the depletion of them results in reduced neutralizing 413 activity in ZIKV-infected patient serum [24, 47] . We also report here that only Committee of Tsinghua University (16-ZLQ9).
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